BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 12393581)

  • 41. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Stock W
    Leuk Lymphoma; 2010 Feb; 51(2):188-98. PubMed ID: 20001232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib for relapsed BCR/ABL positive leukemias.
    Ottmann OG; Wassmann B; Hoelzer D
    Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
    [No Abstract]   [Full Text] [Related]  

  • 43. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hoelzer D; Gökbuget N; Ottmann OG
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):32-7. PubMed ID: 12447850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Sawyers CL
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy.
    Ohno R;
    Curr Hematol Malig Rep; 2006 Sep; 1(3):180-7. PubMed ID: 20425349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
    Thomas DA; O'Brien S; Cortes J; Kantarjian H
    Curr Hematol Malig Rep; 2007 Jul; 2(3):183-9. PubMed ID: 20425368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
    Liu-Dumlao T; Kantarjian H; Thomas DA; O'Brien S; Ravandi F
    Curr Oncol Rep; 2012 Oct; 14(5):387-94. PubMed ID: 22669492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ohno R
    Curr Oncol Rep; 2008 Sep; 10(5):379-87. PubMed ID: 18706265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia.
    Li X; Zhang J; Liu F; Liu T; Zhang R; Chen Y; Guo Y; Fang Y; Xu X; Pui CH; Zhu X
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):660-666. PubMed ID: 37301632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yanada M; Ohno R; Naoe T
    Int J Hematol; 2009 Jan; 89(1):3-13. PubMed ID: 19093166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Case Report of Imatinib-induced Acute Heart Failure and Literature Review.
    Li Z; Qu W; He X; Zhao X; Luo Y; Wang J
    J Coll Physicians Surg Pak; 2022 Jan; 32(1):114-116. PubMed ID: 34983162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of acute lymphoblastic leukaemia : a new era.
    Apostolidou E; Swords R; Alvarado Y; Giles FJ
    Drugs; 2007; 67(15):2153-71. PubMed ID: 17927282
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.
    Rousselot P; Delannoy A
    Drugs Aging; 2011 Sep; 28(9):749-64. PubMed ID: 21913740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
    Scheuring UJ; Pfeifer H; Wassmann B; Bruck P; Atta J; Petershofen EK; Gehrke B; Gschaidmeier H; Hoelzer D; Ottmann OG
    Blood; 2003 Jan; 101(1):85-90. PubMed ID: 12393581
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
    Ottmann OG; Hoelzer D
    Hematol J; 2002; 3(1):2-6. PubMed ID: 11960387
    [No Abstract]   [Full Text] [Related]  

  • 58. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
    Goldman J
    Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Cross SA; Lyseng-Williamson KA
    Drugs; 2007; 67(17):2645-54. PubMed ID: 18034597
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.